Muscle Invasive Bladder Urothelial Carcinoma Clinical Trials
5 recruiting trials for Muscle Invasive Bladder Urothelial Carcinoma. Eligibility criteria explained in plain English.
TrialFinderData lists 5 Muscle Invasive Bladder Urothelial Carcinoma clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 2 (3 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Matthew Galsky (1), National Cancer Institute (NCI) (1), Fox Chase Cancer Center (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Pembrolizumab (drug, 2 trials), followed by Enfortumab vedotin, Biospecimen Collection.
Track Muscle Invasive Bladder Urothelial Carcinoma trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Patients with MIBC will receive 3 cycles (C1-C3) of induction enfortumab vedotin plus pembrolizumab followed by restaging including MRI of the bladder, urine cytology, and...
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle...
This phase II trial tests the effect of giving pembrolizumab in combination with radiation therapy after chemotherapy in preventing surgery to remove the bladder in patients with...
Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
This trial aims at investigating the diagnostic ability of a combined diagnostic panel including systematic endoscopic evaluation (SEE), blood-based ctDNA assay, and urine-based...
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma
Urothelial carcinomas are one of the most commonly diagnosed cancers worldwide. Postoperative patients carry a poor prognosis with an estimated five-year disease-specific survival...
Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy
Observational study on the quality of life and pathological state of patients underwent radical cystectomy.
Explore Other Conditions
Frequently Asked Questions
There are currently 5 clinical trials for Muscle Invasive Bladder Urothelial Carcinoma, with 5 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Muscle Invasive Bladder Urothelial Carcinoma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Muscle Invasive Bladder Urothelial Carcinoma, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.